Retrospective Study
Copyright ©The Author(s) 2024.
World J Nephrol. Mar 25, 2024; 13(1): 88028
Published online Mar 25, 2024. doi: 10.5527/wjn.v13.i1.88028
Table 3 Responses to treatment and final clinical outcomes of focal segmental glomerulosclerosis morphologic variants in patients who received treatment, n (%)
Outcomes
All patients (n = 302)
NOS (n = 160)
TIP (n = 89)
COL (n = 53)
P value
Complete remission84 (27.8)40 (25.0)42 (47.1)2 (3.7)< 0.001
Partial remission49 (16.2)27 (16.8)11 (12.4)11 (20.8)0.005
No remission169 (55.9)93 (58.1)36 (40.4)40 (75.5)< 0.001
Relapse40 (13.2)27 (16.9)9 (10.1)4 (7.5)0.029
Final eGFR (mL/min/1.73 m2), mean ± SD92.1 ± 57.794.1 ± 59.1110.3 ± 52.860.0 ± 46.9< 0.001
Doubling of serum creatinine at last follow-up30 (9.9)16 (10.0)1 (1.1)13 (24..5)< 0.001
Kidney failure36 (11.19)13 (8.1)0 (0.0)23 (43.3)< 0.001
Hemodialysis18 (5.9)5 (3.1)0 (0.0)13(24.5)< 0.001
Expired4 (1.3)3 (1.8)0 (0.0)1 (1.8)0.429